DD255477A5 - Verfahren zur herstellung von stabilisierten menschlichen gewebe-plasminogen-aktivator-zusammensetzungen - Google Patents
Verfahren zur herstellung von stabilisierten menschlichen gewebe-plasminogen-aktivator-zusammensetzungen Download PDFInfo
- Publication number
- DD255477A5 DD255477A5 DD86297695A DD29769586A DD255477A5 DD 255477 A5 DD255477 A5 DD 255477A5 DD 86297695 A DD86297695 A DD 86297695A DD 29769586 A DD29769586 A DD 29769586A DD 255477 A5 DD255477 A5 DD 255477A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- item
- composition
- arginine
- argininium
- concentration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 239000012190 activator Substances 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title description 5
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims abstract description 81
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims abstract description 81
- 229960000187 tissue plasminogen activator Drugs 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000000872 buffer Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-O argininium(1+) Chemical compound NC(=[NH2+])NCCCC([NH3+])C([O-])=O ODKSFYDXXFIFQN-UHFFFAOYSA-O 0.000 claims abstract 3
- -1 argininium ions Chemical class 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 230000009466 transformation Effects 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 description 38
- 229960003121 arginine Drugs 0.000 description 38
- 235000009697 arginine Nutrition 0.000 description 38
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 230000000694 effects Effects 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 12
- 238000004108 freeze drying Methods 0.000 description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 10
- 229920000053 polysorbate 80 Polymers 0.000 description 10
- 229940068968 polysorbate 80 Drugs 0.000 description 10
- CCTIOCVIZPCTGO-BYPYZUCNSA-N phosphoarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NP(O)(O)=O CCTIOCVIZPCTGO-BYPYZUCNSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 102000001938 Plasminogen Activators Human genes 0.000 description 5
- 108010001014 Plasminogen Activators Proteins 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 229940127126 plasminogen activator Drugs 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229960003589 arginine hydrochloride Drugs 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000005496 eutectics Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940074404 sodium succinate Drugs 0.000 description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000008362 succinate buffer Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000003804 extraction from natural source Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 102000047823 human PLAT Human genes 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/811,081 US4777043A (en) | 1985-12-17 | 1985-12-17 | Stabilized human tissue plasminogen activator compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD255477A5 true DD255477A5 (de) | 1988-04-06 |
Family
ID=25205495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD86297695A DD255477A5 (de) | 1985-12-17 | 1986-12-16 | Verfahren zur herstellung von stabilisierten menschlichen gewebe-plasminogen-aktivator-zusammensetzungen |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US4777043A (xx) |
| EP (1) | EP0228862B1 (xx) |
| JP (2) | JPH0714886B2 (xx) |
| KR (1) | KR950010322B1 (xx) |
| AT (1) | ATE79273T1 (xx) |
| AU (1) | AU600246B2 (xx) |
| DD (1) | DD255477A5 (xx) |
| DE (2) | DE3686410T2 (xx) |
| DK (1) | DK174203B1 (xx) |
| ES (1) | ES2044840T3 (xx) |
| FI (1) | FI88873C (xx) |
| FR (1) | FR2591485B1 (xx) |
| GB (1) | GB2184354B (xx) |
| GR (1) | GR3006078T3 (xx) |
| HU (1) | HU200101B (xx) |
| IE (1) | IE59060B1 (xx) |
| IL (1) | IL80904A (xx) |
| MY (1) | MY102185A (xx) |
| NO (1) | NO168988C (xx) |
| NZ (1) | NZ218612A (xx) |
| PH (1) | PH24716A (xx) |
| PT (1) | PT83933B (xx) |
| ZA (1) | ZA869457B (xx) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3687255T2 (de) * | 1985-09-10 | 1993-05-06 | Eisai Co Ltd | Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung. |
| JPH0672105B2 (ja) * | 1985-10-02 | 1994-09-14 | 持田製薬株式会社 | 血栓溶解剤及びその製法 |
| US5453363A (en) * | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
| US5034225A (en) * | 1985-12-17 | 1991-07-23 | Genentech Inc. | Stabilized human tissue plasminogen activator compositions |
| JP2708749B2 (ja) * | 1987-08-10 | 1998-02-04 | エーザイ株式会社 | 修飾型ｔＰＡ含有注射用組成物 |
| DE3877529T2 (de) * | 1987-10-23 | 1996-11-07 | Centre Regional De Transfusion | Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung. |
| US4898826A (en) * | 1987-12-10 | 1990-02-06 | Invitron Corporation | Method to solubilize tissue plasminogen activator |
| HU206367B (en) * | 1988-04-30 | 1992-10-28 | Sandoz Ag | Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts |
| US4980165A (en) * | 1989-01-27 | 1990-12-25 | Genetics Institute, Inc. | Pharmaceutical formulations of plasminogen activator proteins |
| DE3903581A1 (de) * | 1989-02-07 | 1990-08-16 | Boehringer Mannheim Gmbh | Gewebs-plasminogenaktivator-derivat |
| US6207151B1 (en) * | 1989-09-21 | 2001-03-27 | Mitsui Chemicals Inc. | Aqueous solution of t-PA |
| JP2520975B2 (ja) * | 1989-09-21 | 1996-07-31 | 三井東圧化学株式会社 | 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤 |
| DE3942143A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | T-pa pro stabilisierung |
| DE3942141A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | K2p pro-stabilisierung |
| DE3942145A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | T-pa-solubilisierung |
| DE3942142A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | Stabilisierung von glykosyliertem t-pa |
| DE3942144A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | Stabilisierung von k1k2p pro |
| US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| DE19606551C2 (de) * | 1996-02-22 | 2000-06-08 | Basotherm Gmbh | rt-PA zur Prävention des Nachstars nach Kataraktoperation |
| US5972912A (en) * | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
| DE60009926T2 (de) * | 1999-08-17 | 2005-04-07 | Novo Nordisk Health Care Ag | Stabilisierung von gefriergetrocknetem kuchen |
| US6586574B1 (en) | 1999-08-17 | 2003-07-01 | Nn A/S | Stabilization of freeze-dried cake |
| JP4659320B2 (ja) * | 1999-11-04 | 2011-03-30 | ジェネンテック， インコーポレイテッド | プラスミノーゲン活性化因子の逆相ｈｐｌｃアッセイ |
| US7282219B2 (en) | 2000-03-31 | 2007-10-16 | Kirin Beer Kabushiki Kaisha | Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability |
| JP2005502710A (ja) * | 2001-09-07 | 2005-01-27 | グローバル バイオテック インコーポレイテッド | ヒト組織ウロキナーゼ型プラスミノーゲン活性化因子製剤 |
| US20110179558A1 (en) * | 2009-07-29 | 2011-07-28 | International Enviroguard Systems, Inc. | Breathable Protective Fabric and Garment |
| EP2968574A1 (en) * | 2013-03-14 | 2016-01-20 | Allergan, Inc. | Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK98833C (da) * | 1961-04-25 | 1964-05-25 | Novo Terapeutisk Labor As | Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger. |
| EP0112940B1 (en) * | 1982-12-30 | 1986-10-15 | Kowa Company, Ltd. | Method of producing a tissue plasminogen activator and composition comprising same |
| JPS59196824A (ja) * | 1983-04-21 | 1984-11-08 | Kowa Co | 吸着防止剤 |
| EP0156169B1 (en) * | 1984-02-29 | 1991-12-18 | Asahi Kasei Kogyo Kabushiki Kaisha | An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method |
| NO175216C (no) * | 1985-04-22 | 1994-09-14 | Genentech Inc | Fremgangsmåte for fremstilling av human vevs-plasminogen-aktivator, DNA sekvens, replikerbar ekspresjonsvektor og cellekultur |
| CH664495A5 (de) * | 1985-05-28 | 1988-03-15 | Wellcome Found | Pharmazeutische formulierung. |
| US4929444A (en) * | 1985-05-28 | 1990-05-29 | Burroughs Wellcome Co. | Low pH pharmaceutical formulation containing t-PA |
| ZW14486A1 (en) * | 1985-07-29 | 1986-10-22 | Smithkline Beckman Corp | Pharmaceutical dosage unit |
| DE3687255T2 (de) * | 1985-09-10 | 1993-05-06 | Eisai Co Ltd | Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung. |
| JPH0672105B2 (ja) * | 1985-10-02 | 1994-09-14 | 持田製薬株式会社 | 血栓溶解剤及びその製法 |
| DE3537708A1 (de) * | 1985-10-23 | 1987-04-23 | Boehringer Mannheim Gmbh | Verfahren zur aktivierung von t-pa nach expression in prokaryonten |
| JPS62120321A (ja) * | 1985-11-20 | 1987-06-01 | Eisai Co Ltd | ｔＰＡ含有医薬組成物 |
| JPS62283932A (ja) * | 1986-05-29 | 1987-12-09 | Green Cross Corp:The | 組織プラスミノ−ゲンアクチベ−タの乾燥製剤 |
-
1985
- 1985-12-17 US US06/811,081 patent/US4777043A/en not_active Expired - Lifetime
-
1986
- 1986-12-08 IL IL80904A patent/IL80904A/xx not_active IP Right Cessation
- 1986-12-12 NZ NZ218612A patent/NZ218612A/xx unknown
- 1986-12-15 PT PT83933A patent/PT83933B/pt unknown
- 1986-12-16 DE DE8686309811T patent/DE3686410T2/de not_active Expired - Lifetime
- 1986-12-16 HU HU865225A patent/HU200101B/hu unknown
- 1986-12-16 DE DE19863642960 patent/DE3642960A1/de not_active Ceased
- 1986-12-16 DK DK198606057A patent/DK174203B1/da not_active IP Right Cessation
- 1986-12-16 PH PH34602A patent/PH24716A/en unknown
- 1986-12-16 AU AU66610/86A patent/AU600246B2/en not_active Expired
- 1986-12-16 FR FR8617593A patent/FR2591485B1/fr not_active Expired
- 1986-12-16 AT AT86309811T patent/ATE79273T1/de not_active IP Right Cessation
- 1986-12-16 KR KR1019860010747A patent/KR950010322B1/ko not_active Expired - Lifetime
- 1986-12-16 IE IE327986A patent/IE59060B1/en not_active IP Right Cessation
- 1986-12-16 ES ES86309811T patent/ES2044840T3/es not_active Expired - Lifetime
- 1986-12-16 EP EP86309811A patent/EP0228862B1/en not_active Expired - Lifetime
- 1986-12-16 DD DD86297695A patent/DD255477A5/de unknown
- 1986-12-16 NO NO865079A patent/NO168988C/no not_active IP Right Cessation
- 1986-12-16 GB GB8629981A patent/GB2184354B/en not_active Revoked
- 1986-12-17 FI FI865159A patent/FI88873C/fi not_active IP Right Cessation
- 1986-12-17 JP JP61302767A patent/JPH0714886B2/ja not_active Expired - Lifetime
- 1986-12-17 ZA ZA869457A patent/ZA869457B/xx unknown
-
1987
- 1987-10-01 MY MYPI87002760A patent/MY102185A/en unknown
-
1988
- 1988-03-28 US US07/173,854 patent/US4908205A/en not_active Expired - Lifetime
-
1992
- 1992-10-26 GR GR920402407T patent/GR3006078T3/el unknown
-
1994
- 1994-08-04 JP JP6183274A patent/JPH07173076A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3686410T2 (de) | Stabilisierte zusammensetzungen von menschlichen aktivatoren des gewebeplasminogens. | |
| DE69629209T2 (de) | Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose | |
| DE69701548T2 (de) | Rekombinanten Faktor VIII enthaltendes stabilisiertes albuminfreies Präparat mit niedrigem Zuckergehalt | |
| DE69736177T2 (de) | Mit aminosäuren stabilisierte erythropoietinlösung | |
| DE60125986T3 (de) | Pharmazeutische Zusammensetzungen mit Botulinum Toxin | |
| DE69828330T2 (de) | Aktiviertes Protein C Formulierungen | |
| DE3520228C2 (de) | Wasserlösliche bioaktive Trockenfeststoffzusammensetzung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate | |
| DE69729786T2 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
| EP0508194B1 (de) | Stabilisierte Faktor VIII-Präparationen | |
| DE69532970T3 (de) | Sprühgetrocknetes erythropoietin | |
| DE69334134T2 (de) | Wässrige Formulierung enthaltend Menschliches Wachstumshormon | |
| DE69328519T2 (de) | Chondroitinase, Herstellungsverfahren und pharmazeutische Zusammensetzung | |
| DE69630291T2 (de) | Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält | |
| EP0733702B1 (de) | Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung | |
| DE60024268T2 (de) | Zusammensetzungen mit stabilem faktor viii | |
| DE3400413C2 (xx) | ||
| DE3729863A1 (de) | Stabilisierte erythropoietin-lyophilisate | |
| DE60009529T2 (de) | Pharmazeutische zusammensetzung aus fibrinolytischem mittel | |
| WO1997014429A1 (de) | Stabile pharmazeutische darreichungsformen enthaltend parathormon | |
| US5034225A (en) | Stabilized human tissue plasminogen activator compositions | |
| DE69420872T2 (de) | Hgh enthaltende pharmazeutische zubereitungen | |
| EP0746334B1 (de) | Pharmazeutisches präparat enthaltend plasminogenaktivatoren | |
| DE60009926T2 (de) | Stabilisierung von gefriergetrocknetem kuchen | |
| DE69417397T2 (de) | Lösung, die igf-1 enthält | |
| DE69101784T2 (de) | Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF04 | In force in the year 2004 |
Expiry date: 20061217 |